Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDC + ConS + UFO refers to a combination approach used in HIV-1 vaccine research, specifically involving the use of consensus sequence (ConS) HIV-1 envelope glycoprotein trimers that are uncleaved and prefusion-optimized (UFO), with crosslinking by EDC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide). This formulation is designed to present native-like trimeric Env antigens to the immune system, aiming to elicit broadly neutralizing antibodies against diverse HIV strains. The "EDC" component refers to a chemical crosslinker used for stabilizing protein structures; "ConS" denotes a consensus sequence immunogen representing common features across multiple HIV strains; and "UFO" stands for uncleaved prefusion optimized, describing an engineered form of the Env trimer that mimics its natural conformation on the virus surface. These constructs are under investigation as part of next-generation vaccine candidates targeting improved immunogenicity and breadth of response[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EDC + ConS + UFO.